Pegfilgrastim Biosimilars Market - By Application (Chemotherapy Induced Neutropenia, Transplantation, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Mail Order/Online Pharmacies), And By Region, Opportunities And Strategies – Global Pegfilgrastim Biosimilars Market Forecast To 2030

Starting Price : $4000.00 | Pages : 206 | Published : December 2020 | SKU CODE : o&s198 | Format :

Request Sample

Pegfilgrastim Biosimilars Market Definition

The pegfilgrastim biosimilars market consists of sales of pegfilgrastim biosimilar drugs and related services. The drugs are used during the course of cancer treatment in order to reduce the infection risk for those patients undergoing immunosuppressant treatments, such as chemotherapy. The drug has further applications where protection from infections where immune system is compromised, such as in bone marrow transplants.

Biosimilars are biological products which are being produced to be identical to a biologic already approved, known as reference drugs. Biosimilars should have similar safety and efficacy compared to the reference biologic product. Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue filgrastim.

Pegfilgrastim Biosimilars Market Size

The global pegfilgrastim biosimilars market reached a value of nearly $876.0 million in 2019.  The market is expected to grow from $876.0 million in 2019 to $1,119.2million in 2023 at a rate of 6.3%. The growth is mainly due to an increased prevalence of cancer and increased adoption of the biosimilars. The market is expected to stabilize and reach $1,538.6 million in 2025 and $3,598.3 million in 2030.

Growth in the historic period resulted from government initiatives for biosimilars, increase in healthcare expenditure, and increase in pharmaceutical R&D expenditure and low costs of biosimilars. This growth was restricted by low rate of drug approvals, and lack of awareness on biosimilars among primary care physicians and specialists.

Going forward, aging population, increase in healthcare access and rising prevalence of chronic diseases are expected to drive the market. Effect of COVID-19, stringent regulations related to biosimilar approvals and prolonged production and approval time are major factors that could hinder the growth of the pegfilgrastim biosimilars market in the future.

Pegfilgrastim Biosimilars Market Drivers

The key drivers of the pegfilgrastim biosimilars market include:

Rising Prevalence Of Chronic Diseases

The rising prevalence of chronic diseases such as cancer is expected to be a major driver of the pegfilgrastim biosimilars market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and leave people suffering from these diseases more vulnerable to chronic diseases, thus driving the need for pegfilgrastim biosimilars. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. According to the National Cancer Institute (NCI) report, it was estimated that 1.7 million new cases of cancer are diagnosed in the US in 2019, and 606,880 people are expected to die from the disease. Therefore, the rise in the prevalence of chronic diseases is projected to propel the growth of the market.

Pegfilgrastim Biosimilars Market Restraints

The key restraints on the pegfilgrastim biosimilars market include:

Effect Of COVID-19

The market is expected to be negatively impacted by the COVID-19 situation and its economic implications. With the majority of countries suffering from the impact of COVID-19, many countries are looking for a way to cure COVID-19. The pandemic has had a serious and disruptive effect on the conduct of oncology clinical trials, with both immediate and delayed consequences. The short-term effects include research staff and resources being reassigned to deal with COVID patients. In the longer term, trials testing treatments for COVID-19 have been prioritized. A sharp reduction in recruitment to ongoing trials and a delay in the planned launch of new oncology studies is expected to negatively impact the market. The market is also expected to be negatively impacted by patients preferring the biologic Neulasta due to its option of an on-body injector which allowed immunocompromised patients undergoing chemotherapy to skip at least a couple of in-person visits to the infusion center without exposing them to higher risks of neutropenia and infection. Therefore there was a higher demand for the biologic, thus restraining the growth of the market, as biosimilars are only available for administration by syringe at this time.

Pegfilgrastim Biosimilars Market Trends

Major trends shaping the pegfilgrastim biosimilars market include:

Revised FDA Regulations To Facilitate Biosimilar Drug Development

The US Food and Drug Administration (FDA) has revised its regulations to eliminate outdated biologics and biosimilar requirements, thus allowing drug manufacturers to employ new manufacturing technologies and testing capabilities. Standard preparations (standard solutions containing a precisely known concentration of an element), which help to ensure safety, purity and potency of biologics/biosimilar, can now be obtained from sources other than the FDA’s Center for Biologics Evaluation and Research (CBER), or can be developed internally by the biologics license applicant. The FDA has also removed a rule (Section 610.21 of FDA code) which specifies minimal potency limits to be met for certain antibodies and antigens. In addition, the FDA is also updating regulations (Section 610.53 of FDA code) regarding storage periods and storage conditions for biologics. These amendments in regulations are expected to increase regulatory flexibility by allowing the pharmaceutical industry and the FDA to incorporate current scientific technologies in the manufacture of licensed biological products. The average yearly number of new drug approvals was 25 between 2000 and 2009, and 41 between 2010 and 2018. The new biologic product approvals increased from a median of 5 between 2000 and 2013, to 12 between 2014 and 2018.

Robust Research & Development

The pegfilgrastim biosimilar market is witnessing robust research and development activities. These research and development activities have led to increasing success rates in clinical trials for biosimilars. Research and development is being carried out by market leaders in the biosimilars market as they continuously strive to make breakthroughs in the market in the form of new and effective biosimilars. For instance, Fresenius Kabi is developing MSB11455, a biosimilar which stimulates the growth of white blood cells that are essential to fight infections, a common adverse event in patients receiving chemotherapy for cancer. MSB11455 was developed in Switzerland by Fresenius Kabi’s immunology and oncology research lab. Currently, the drug is in Phase I clinical study for oncology patients. In June 2020, Pfizer, an American multinational pharmaceutical company, received approval from the US Food and Drug Administration to introduce its biosimilar drug for lowering the incidence of infection as manifested by febrile neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs.

Opportunities And Recommendations In The Pegfilgrastim Biosimilars Market

Opportunities: The top opportunities in the pegfilgrastim biosimilars market segmented by application will arise in the chemotherapy induced neutropenia segment, which will gain $194.2 million of global annual sales by 2023. The top opportunities in the pegfilgrastim biosimilars market segmented by distribution channel will arise in the hospital pharmacies segment, which will gain $127.6 million of global annual sales by 2023. The pegfilgrastim biosimilars market size will gain the most in the USA at $120.2 million. Market-trend-based strategies for the pegfilgrastim biosimilars market include taking advantage of the less stringent regulations to develop new and improved biosimilars, investing extensively in R&D activities for the development of effective and innovative biologics, focusing on establishing strategic partnerships with the large players to expand their research and developments activities in new drug developments and increasing their focus on M&A growth strategies to expand the customer base and their geographic markets.. Player-adopted strategies in the pegfilgrastim biosimilars market include investing in expanding operations in different geographies, improving infrastructure and in acquisitions and mergers to strengthen their service offerings.

Recommendations: To take advantage of the opportunities, the business research company recommends the pegfilgrastim biosimilars companies to focus on strategic partnerships, focus on research & development, expand in emerging markets, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, companies should focus on creating awareness, and focus on creating awareness among patients and doctors.

Pegfilgrastim Biosimilars Market Segmentation

The pegfilgrastim biosimilars market is segmented by application, by distribution channel
By Application- The pegfilgrastim biosimilars market can be segmented by application
    • a. Chemotherapy Induced Neutropenia
    • b. Transplantation
    • c. Others
The pegfilgrastim biosimilars market is segmented by application into chemotherapy induced neutropenia, transplantation and others. The chemotherapy induced neutropenia was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 75.2% of the total market in 2019. Going forward, chemotherapy induced neutropenia segment is also expected to be the fastest growing segment in the pegfilgrastim biosimilar market, at a CAGR of 18.9%.
By Distribution Channel- The pegfilgrastim biosimilars market can be segmented by distribution channel
    • a. Hospital Pharmacies
    • b. Retail Pharmacies
    • c. Mail Order/Online Pharmacies
The pegfilgrastim biosimilars market is also segmented by distribution channel into hospital pharmacies, retail pharmacies and mail order/ online pharmacies. The hospital pharmacies was the largest segment of the pegfilgrastim biosimilars market by application, accounting for 89.8% of the total market in 2019. Going forward, the retail pharmacies segment is expected to be the fastest growing segment in the pegfilgrastim biosimilars market, at a CAGR of 30.4%.
By Geography- The pegfilgrastim biosimilars market segmented into
    • o Asia Pacific
      • China
      • India
      • Japan
      • Australia
      • Indonesia
      • South Korea
    • o North America
      • USA
    • o South America
      • Brazil
    • o Western Europe
      • UK
      • Germany
      • France
    • o Eastern Europe
      • Russia
    • o Middle East
    • o Africa
North America was the largest region in the global pegfilgrastim biosimilars market, accounting for 51.1% of the total in 2019. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the pegfilgrastim biosimilars market will be Middle East and Asia Pacific, where growth will be at CAGRs of 34.8% and 30.3% respectively.

Pegfilgrastim Biosimilars Market Competitive Landscape

Major Competitors are:
    • • Coherus Biosciences Inc.
    • • Biocon
    • • Mylan
    • • Sandoz (Novartis)
Other Competitors include:
    • • Apotex Pty Ltd
    • • Kyowa Kirin Co., Ltd
    • • Qilu Pharmaceutical
    • • Gennova Biopharmaceuticals Limited
    • • Lupin Limited
    • • Dr. Reddy’s Laboratories Ltd
    • • Fresenius Kabi
    • • Napp Pharmaceuticals
    • • Pfizer

    Table Of Contents

    1. Pegfilgrastim Biosimilars Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction

    6.1.1. Segmentation By Geography

    6.1.2. Segmentation By Application

    6.1.3. Segmentation By Distribution Channel

    7. Pegfilgrastim Biosimilars Market Characteristics

    7.1. Market Definition

    7.2. Market Segmentation By Application

    7.2.1. Chemotherapy Induced Neutropenia

    7.2.2. Transplantation

    7.2.3. Others

    7.3. Market Segmentation By Distribution Channel

    7.3.1. Hospital Pharmacies

    7.3.2. Retail Pharmacies

    7.3.3. Mail Order/Online Pharmacies

    8. Pegfilgrastim Biosimilars Market Trends And Strategies

    8.1. Revised FDA Regulations To Facilitate Biosimilar Drug Development

    8.2. Robust Research & Development

    8.3. Large Number Of Strategic Partnerships

    8.4. Growing Mergers And Acquisitions

    9. Pegfilgrastim Biosimilars Market, COVID Impact Analysis

    9.1. Impact Of COVID-19 On Major Pegfilgrastim Biosimilar Market Player Biocon Biologics

    10. Global Pegfilgrastim Biosimilars Market Size And Growth

    10.1. Market Size

    10.2. Historic Market Growth, 2015 – 2019, Value ($ Million)

    10.2.1. Drivers Of The Market 2015 – 2019

    10.2.2. Restraints Of The Market 2015-2019

    10.3. Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    10.3.1. Drivers Of The Market 2019 – 2023

    10.3.2. Restraints On The Market 2019 – 2023

    11. Global Pegfilgrastim Biosimilars Market Segmentation

    11.1. Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.1.1. Chemotherapy induced neutropenia

    11.1.2. Transplantation

    11.1.3. Others

    11.2. Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    11.2.1. Hospital pharmacies

    11.2.2. Retail pharmacies

    11.2.3. Mail-Order pharmacies

    12. Pegfilgrastim Biosimilars Market, Regional And Country Analysis

    12.1. Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    12.2. Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13. Asia-Pacific Pegfilgrastim Biosimilars Market

    13.1. Asia-Pacific Pegfilgrastim Biosimilars Market Overview

    13.1.1. Region Information

    13.1.2. Impact Of COVID-19

    13.1.3. Market Information

    13.1.4. Background Information

    13.1.5. Government Initiatives

    13.1.6. Regulations

    13.1.7. Regulatory Bodies

    13.1.8. Major Associations

    13.1.9. Taxes Levied

    13.1.10. Corporate Tax Structure

    13.1.11. Investments

    13.1.12. Major Companies

    13.2. Asia-Pacific Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.3. Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.4. Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.5. Asia-Pacific Pegfilgrastim Biosimilars Market: Country Analysis

    13.6. China Pegfilgrastim Biosimilars Market

    13.7. China Pegfilgrastim Biosimilars Market Overview

    13.7.1. Country Information

    13.7.2. Impact Of COVID-19

    13.7.3. Market Information

    13.7.4. Background Information

    13.7.5. Government Initiatives

    13.7.6. Regulations

    13.7.7. Regulatory Bodies

    13.7.8. Major Associations

    13.7.9. Taxes Levied

    13.7.10. Corporate Tax Structure

    13.7.11. Major Companies

    13.8. China Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.9. China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.10. India Pegfilgrastim Biosimilars Market

    13.11. India Pegfilgrastim Biosimilars Market Overview

    13.11.1. Country Information

    13.11.2. Impact Of COVID-19

    13.11.3. Market Information

    13.11.4. Background Information

    13.11.5. Government Initiatives

    13.11.6. Regulations

    13.11.7. Regulatory Bodies

    13.11.8. Major Associations

    13.11.9. Taxes Levied

    13.11.10. Corporate Tax Structure

    13.11.11. Investments

    13.11.12. Major Companies

    13.12. India Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.13. India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.14. Japan Pegfilgrastim Biosimilars Market

    13.15. Japan Pegfilgrastim Biosimilars Market Overview

    13.15.1. Country Information

    13.15.2. Impact Of COVID-19

    13.15.3. Market Information

    13.15.4. Background Information

    13.15.5. Government Initiatives

    13.15.6. Regulations

    13.15.7. Regulatory Bodies

    13.15.8. Major Associations

    13.15.9. Taxes Levied

    13.15.10. Corporate Tax Structure

    13.15.11. Major Companies

    13.16. Japan Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.17. Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.18. Australia Pegfilgrastim Biosimilars Market

    13.19. Australia Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.20. Australia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.21. Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.22. Indonesia Pegfilgrastim Biosimilars Market

    13.23. Indonesia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.24. Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    13.25. South Korea Pegfilgrastim Biosimilars Market

    13.26. South Korea Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    13.27. South Korea Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    13.28. South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14. Western Europe Pegfilgrastim Biosimilars Market

    14.1. Western Europe Pegfilgrastim Biosimilars Market Overview

    14.1.1. Region Information

    14.1.2. COVID Impact

    14.1.3. Market Information

    14.1.4. Background Information

    14.1.5. Government Initiatives

    14.1.6. Regulations

    14.1.7. Regulatory Bodies

    14.1.8. Major Associations

    14.1.9. Taxes levied

    14.1.10. Corporate Tax Structure

    14.1.11. Investments

    14.1.12. Major Companies

    14.2. Western Europe Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.3. Western Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.4. Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.5. Western Europe Pegfilgrastim Biosimilars Market: Country Analysis

    14.6. UK Pegfilgrastim Biosimilars Market

    14.7. UK Pegfilgrastim Biosimilars Market Overview

    14.7.1. Country Information

    14.7.2. COVID Impact

    14.7.3. Market Information

    14.7.4. Background Information

    14.7.5. Government Initiatives

    14.7.6. Regulations

    14.7.7. Regulatory Bodies

    14.7.8. Major Associations

    14.7.9. Taxes levied

    14.7.10. Corporate Tax Structure

    14.7.11. Investments

    14.7.12. Major Companies

    14.8. UK Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.9. UK Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.10. UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.11. Germany Pegfilgrastim Biosimilars Market

    14.12. Germany Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.13. Germany Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.14. Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    14.15. France Pegfilgrastim Biosimilars Market

    14.16. France Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    14.17. France Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    14.18. France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15. Eastern Europe Pegfilgrastim Biosimilars Market

    15.1. Eastern Europe Pegfilgrastim Biosimilars Market Overview

    15.1.1. Region Information

    15.1.2. COVID Impact

    15.1.3. Market Information

    15.1.4. Background Information

    15.1.5. Government Initiatives

    15.1.6. Regulations

    15.1.7. Regulatory Bodies

    15.1.8. Major Associations

    15.1.9. Taxes levied

    15.1.10. Corporate Tax Structure

    15.1.11. Investments

    15.1.12. Major Companies

    15.2. Eastern Europe Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.3. Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    15.4. Eastern Europe Pegfilgrastim Biosimilars Market: Country Analysis

    15.5. Russia Pegfilgrastim Biosimilars Market

    15.6. Russia Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    15.7. Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16. North America Pegfilgrastim Biosimilars Market

    16.1. North America Pegfilgrastim Biosimilars Market Overview

    16.1.1. Region Information

    16.1.2. Impact Of COVID-19

    16.1.3. Market Information

    16.1.4. Background Information

    16.1.5. Government Initiatives

    16.1.6. Regulations

    16.1.7. Regulatory Bodies

    16.1.8. Major Associations

    16.1.9. Taxes Levied

    16.1.10. Corporate Tax Structure

    16.1.11. Investments

    16.1.12. Major Companies

    16.2. North America Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.3. North America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.4. North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    16.5. North America Pegfilgrastim Biosimilars Market: Country Analysis

    16.6. USA Pegfilgrastim Biosimilars Market

    16.7. USA Pegfilgrastim Biosimilars Market Overview

    16.7.1. Country Information

    16.7.2. Impact Of COVID-19

    16.7.3. Market Information

    16.7.4. Background Information

    16.7.5. Government Initiatives

    16.7.6. Regulations

    16.7.7. Regulatory Bodies

    16.7.8. Major Associations

    16.7.9. Taxes Levied

    16.7.10. Corporate Tax Structure

    16.7.11. Investments

    16.7.12. Major Companies

    16.8. USA Pegfilgrastim Biosimilars Market, Historic Market Growth, 2015 – 2019, Value ($ Million)

    16.9. USA Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    16.10. USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17. South America Pegfilgrastim Biosimilars Market

    17.1. South America Pegfilgrastim Biosimilars Market Overview

    17.1.1. Region Information

    17.1.2. Impact Of COVID-19

    17.1.3. Market Information

    17.1.4. Background Information

    17.1.5. Government Initiatives

    17.1.6. Regulations

    17.1.7. Regulatory Bodies

    17.1.8. Major Associations

    17.1.9. Taxes Levied

    17.1.10. Corporate Tax Structure

    17.1.11. Major Companies

    17.2. South America Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.3. South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    17.4. South America Pegfilgrastim Biosimilars Market: Country Analysis

    17.5. Brazil Pegfilgrastim Biosimilars Market

    17.6. Brazil Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    17.7. Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    18. Middle East Pegfilgrastim Biosimilars Market

    18.1. Middle East Pegfilgrastim Biosimilars Market Overview

    18.1.1. Region Information

    18.1.2. COVID Impact

    18.1.3. Market Information

    18.1.4. Background Information

    18.1.5. Government Initiatives

    18.1.6. Regulations

    18.1.7. Regulatory Bodies

    18.1.8. Major Associations

    18.1.9. Taxes levied

    18.1.10. Corporate Tax Structure

    18.1.11. Investments

    18.1.12. Major Companies

    18.2. Middle East Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    18.3. Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    19. Africa Pegfilgrastim Biosimilars Market

    19.1. Africa Pegfilgrastim Biosimilars Market Overview

    19.1.1. Region Information

    19.1.2. Impact Of COVID-19

    19.1.3. Market Information

    19.1.4. Background Information

    19.1.5. Government Initiatives

    19.1.6. Regulations

    19.1.7. Regulatory Bodies

    19.1.8. Major Associations

    19.1.9. Taxes Levied

    19.1.10. Corporate Tax Structure

    19.1.11. Major Companies

    19.2. Africa Pegfilgrastim Biosimilars Market, Forecast Market Growth, 2019 – 2023, 2025F, 2030F Value ($ Million)

    19.3. Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, Value ($ Million)

    20. Global Pegfilgrastim Biosimilars Market Competitive Landscape

    20.1. Company Profiles

    20.2. Coherus Biosciences Inc.

    20.2.1. Company Overview

    20.2.2. Products And Services

    20.2.3. Business Strategy

    20.2.4. Financial Overview

    20.3. Biocon

    20.3.1. Company Overview

    20.3.2. Products And Services

    20.3.3. Business Strategy

    20.3.4. Financial Overview

    20.4. Mylan

    20.4.1. Company Overview

    20.4.2. Products And Services

    20.4.3. Business Strategy

    20.4.4. Financial Overview

    20.5. Sandoz (Novartis)

    20.5.1. Company Overview

    20.5.2. Products And Services

    20.5.3. Business Strategy

    20.5.4. Financial Overview

    21. Key Mergers And Acquisitions In The Pegfilgrastim Biosimilars Market

    21.1. Ligand Pharmaceuticals Acquired Pfenex

    21.2. True North Acquired Stake In Biocon Biologics

    21.3. Biocon Acquires Pfizer`s R&D Facility To Boost Biosimilars Development

    21.4. Kashiv Pharma Acquired Adello Biologics

    21.5. Mundipharma International Limited Acquired Cinfa Biotech

    21.6. Biocon Merged With Sandoz

    21.7. Fresenius Kabi Acquired The Biosimilars Business Of Merck KGaA

    22. Pegfilgrastim Biosimilars Market Opportunities And Strategies

    22.1. Global Pegfilgrastim Biosimilars Market In 2023 – Countries Offering Most New Opportunities

    22.2. Global Pegfilgrastim Biosimilars Market In 2023 – Segments Offering Most New Opportunities

    22.3. Global Pegfilgrastim Biosimilars Market In 2023 – Growth Strategies

    22.3.1. Market Trend Based Strategies

    22.3.2. Competitor Strategies

    23. Pegfilgrastim Biosimilars Market, Conclusions And Recommendations

    23.1. Conclusions

    23.2. Recommendations

    23.2.1. Product

    23.2.2. Place

    23.2.3. Price

    23.2.4. Promotion

    23.2.5. People

    24. Appendix

    24.1. Market Data Sources

    24.2. Research Methodology

    24.3. Currencies

    24.4. Research Inquiries

    24.5. The Business Research Company

    24.6. Copyright and Disclaimer

List Of Tables

    Table 1: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 2: Global Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 3: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 4: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 8: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 9: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 10: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 11: Asia Pacific Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 12: Asia-Pacific Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 13: Asia-Pacific Per Capita Net Disposable Income, 2015-2019, $
  • Table 14:  Asia Pacific Population By Age Group, 2015-2023, Thousands
  • Table 15: Asia-Pacific Biologics Market Size, 2015-2019, $ Billion
  • Table 16: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 17: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 18: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 19: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 20: China Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 21: China Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 22: China Per Capita Net Disposable Income, 2015-2019, $
  • Table 23:  China Population By Age Group, 2015-2023, Thousands
  • Table 24: China Biologics Market Size, 2015-2019, $ Billion
  • Table 25: China Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 26: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 27: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 28: India Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 29: India Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 30: India Per Capita Net Disposable Income, 2015-2019, $
  • Table 31:  India Population By Age Group, 2015-2023, Thousands
  • Table 32: Asia-Pacific Biologics Market Size, 2015-2019, $ Billion
  • Table 33: India Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 34: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 35: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 36: Japan Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 37: Japan Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 38: Japan Per Capita Net Disposable Income, 2015-2019, $
  • Table 39:  Japan Population By Age Group, 2015-2023, Thousands
  • Table 40: Japan Biologics Market Size, 2015-2019, $ Billion
  • Table 41: Japan Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 42: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 43: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 44: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 45: Australia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 46: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 47: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 48: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 49: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 50: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 51: South Korea Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 52: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 53: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 54: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 55: Western Europe Estimated Average Expenditure, Cancer Prevalence, 2019
  • Table 56: Western Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 57: Western Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 58:  Western Europe Population By Age Group, 2015-2023, Thousands
  • Table 59: Western Europe Biologics Market Size, 2015-2019, $ Billion
  • Table 60: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 61: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 62: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 63: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 64: UK Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 65: UK Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 66: UK Per Capita Net Disposable Income, 2015-2019, $
  • Table 67:  UK Population By Age Group, 2015-2023, Thousands
  • Table 68: UK Biologics Market Size, 2015-2019, $ Billion
  • Table 69: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 70: UK Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 71: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 72: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 73: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 74: Germany Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 75: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 76: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 77: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 78: France Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 79: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 80: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 81: UK Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 82: Eastern Europe Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 83:  Eastern Europe Population By Age Group, 2015-2023, Thousands
  • Table 84: Eastern Europe Per Capita Net Disposable Income, 2015-2019, $
  • Table 85: Eastern Europe Biologics Market Size, 2015-2019, $ Billion
  • Table 86: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 87: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 88: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 89: Russia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 90: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 91: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 92: North America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 93: North America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 94: North America Per Capita Net Disposable Income, 2015-2019, $
  • Table 95:  North America Population By Age Group, 2015-2023, Thousands
  • Table 96: North America Biologics Market Size, 2015-2019, $ Billion
  • Table 97: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 98: North America Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 99: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 100: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 101: North America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 102: USA Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 103: USA Per Capita Net Disposable Income, 2015-2019, $
  • Table 104:  USA Market, Population By Age Group, 2015-2023, Thousands
  • Table 105: USA Biologics Market Size, 2015-2019, $ Billion
  • Table 106: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Table 107: USA Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 108: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 109: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 110: South America Estimated Average Expenditure, Pegfilgrastim Biosimilar Market, Cancer Prevalence, 2019
  • Table 111: South America Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 112:  South America Population By Age Group, 2015-2023, Thousands
  • Table 113: South America Per Capita Net Disposable Income, 2015-2019, $
  • Table 114: South America Biologics Market Size, 2015-2019, $ Billion
  • Table 115: South America Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 116: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 117: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 118: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 119: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 120: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 121: Middle East Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 122: Middle East Per Capita Net Disposable Income, 2015-2019, $
  • Table 123:  Middle East Population By Age Group, 2015-2023, Thousands
  • Table 124: Middle East Biologics Market Size, 2015-2019, $ Billion
  • Table 125: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 126: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 127: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 128: Africa Per Capita Healthcare Expenditure, 2015-2019, $
  • Table 129: Africa Per Capita Net Disposable Income, 2015-2019, $
  • Table 130:  Africa Population By Age Group, 2015-2023, Thousands
  • Table 131: Africa Biologics Market Size, 2015-2019, $ Billion
  • Table 132: Africa Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Table 133: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Table 134: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, $ Million
  • Table 135: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Table 136: Biocon – Financial Performance, 2015 – 2019, $ Billion
  • Table 137: Mylan – Financial Performance, 2015 – 2019, $ Billion
  • Table 138: Sandoz (Novartis) – Financial Performance, 2015 – 2019, $ Billion
  • Table 139: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), 2019 – 2023, By Country
  • Table 140: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2019 – 2023
  • Table 141: Global Pegfilgrastim Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2019 – 2023
  • Table 142: Pegfilgrastim Biosimilars Market Data Sources

List Of Figures

    Figure 1: Global Pegfilgrastim Biosimilars Market Segmentation By Application
  • Figure 2: Global Pegfilgrastim Biosimilars Market Segmentation By Distribution Channel
  • Figure 3: Global Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 4: Global Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 5: Global Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 6: Global Pegfilgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 7: Global Pegfilgrastim Biosimilars Market, By Region, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 8: Global Pegfilgrastim Biosimilars Market, By Country, Historic and Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 9: Asia-Pacific Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 10: Asia-Pacific Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 11: Asia-Pacific Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 12: China Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 13: China Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 14: India Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 15: India Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 16: Japan Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 17: Japan Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 18: Australia Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 19: Australia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 20: Australia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 21: Indonesia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 22: Indonesia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 23: South Korea Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 24: South Korea Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 25: South Korea Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 26: Western Europe Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 27: Western Europe Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 28: Western Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 29: UK Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 30: UK Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 31: UK Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 32: Germany Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 33: Germany Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 34: Germany Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 35: France Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 36: France Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 37: France Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 38: Eastern Europe Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 39: Eastern Europe Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 40: Russia Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 41: Russia Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 42: North America Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 43: North America Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 44: North America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 45: USA Pegfilgrastim Biosimilars Market, Historic, 2015 – 2019, $ Million
  • Figure 46: USA Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 47: USA Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 48: South America Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 49: South America Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 50: Brazil Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 51: Brazil Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 52: Middle East Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 53: Middle East Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 54: Africa Pegfilgrastim Biosimilars Market, Forecast, 2019 – 2023, 2025F, 2030F, $ Million
  • Figure 55: Africa Pegfilgrastim Biosimilars Market, Segmentation By Application, Historic And Forecast, 2015 – 2019, 2023F, 2025F, 2030F, %
  • Figure 56: Global Pegfilgrastim Biosimilars Market, Key Competitor Estimated Market Shares, 2019, Percentage (%)
  • Figure 57: Biocon – Financial Performance, 2015 – 2019, $ Billion
  • Figure 58: Mylan – Financial Performance, 2015 – 2019, $ Billion
  • Figure 59 Sandoz (Novartis) – Financial Performance, 2015 – 2019, $ Billion
Global Psoriasis Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Psoriatic Arthritis Treatment Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Regenerative Medicine For Cartilage Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Radiopharmaceuticals Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Remdesivir Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Research Antibodies and Reagents Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Rituximab Biosimilars Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Respiratory Diseases Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Biosimilar Monoclonal Antibodies Global Market Report 2021 - By Type (Synthetic Chemicals, Biopharmaceuticals), By Application (Chronic & Autoimmune Diseases, Oncology), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), COVID-19 Growth And Change
View Report
Biosimilar Therapeutic Peptides Global Market Report 2021 - By Route Of Administration (Parenteral Route, Transdermal Route), By Application (Cancer, Cardiovascular, Central Nervous Systems, Metabolic Disorders, Infection, Hematological Disorders, Gastrointestinal Disorders, Dermatology, Respiratory Disorders), By Type (Innovative, Generic), COVID-19 Growth And Change
View Report
Rituximab Biosimilars Global Market Report 2021 - By Application (Non-Hodgkin's Lymphoma, Chronic Lymhocytic Leukemia, Rheumatoid Arthritis), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Direct Distribution Channels), By Route Of Administration (Subcutaneous, Intravenous, Molecular Type), COVID-19 Growth And Change
View Report
Biosimilar Hormones Global Market Report 2021 - By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars), By Application (Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics), By Distribution Channel (Hospital And Retail Pharmacy, Online Pharmacy/epharmacy, Speciality Clinics), COVID-19 Growth And Change
View Report
Biosimilar Lymphocyte Modulator Global Market Report 2021 - By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab - A1089-Anti-CD11a Bisoimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Bisoimilar), By Disease (Arthritis, Diabetes, Multiple Myeloma, Enterocolitis, Multiple Sclerosis, Psoriasis), COVID-19 Growth And Change
View Report
Biosimilars Global Market Report 2021 - By Product (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins), By Types (Human Growth Hormone, Erythropoietin, Monoclonal Antibodies, Insulin, Interferon, Granulocyte-Colony Stimulating Factor), By Application (Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases), COVID-19 Growth And Change
View Report
Oncology Biosimilars Global Market Report 2021 - By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), COVID-19 Growth And Change
View Report
Filgrastim Biosimilars Market - By Application (Oncology, Chronic and Autoimmune Diseases, Blood disorders, Growth hormone deficiency, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), And By Region, Opportunities And Strategies – Global Filgrastim Biosimilars Market Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)